Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Lyne

Showing results (31-40 of 45) with videos related to

Pageof 5
Sort By:
Plos One|July 24, 2018
BRD4 amplification facilitates an oncogenic gene expression program in high-grade serous ovarian cancer and confers sensitivity to BET inhibitorsGarrett W Rhyasen, Yi Yao, Jingwen Zhang, et al.
Journal of Medicinal Chemistry|January 5, 2018
Adventures in Scaffold Morphing: Discovery of Fused Ring Heterocyclic Checkpoint Kinase 1 (CHK1) InhibitorsBin Yang, Melissa M Vasbinder, Alexander W Hird, et al.
Bioorganic & Medicinal Chemistry Letters|September 1, 2016
Modulating the strength of hydrogen bond acceptors to achieve low Caco2 efflux for oral bioavailability of PARP inhibitors blocking centrosome clusteringChungang Gu, Michelle L Lamb, Jeffrey W Johannes, et al.
ACS Medicinal Chemistry Letters|June 6, 2014
Structure and Property Based Design of Pyrazolo[1,5-a]pyrimidine Inhibitors of CK2 Kinase with Activity in VivoJames E Dowling, Marat Alimzhanov, Larry Bao, et al.
Science Translational Medicine|June 16, 2017
Targeting KRAS-dependent tumors with AZD4785, a high-affinity therapeutic antisense oligonucleotide inhibitor of KRASSarah J Ross, Alexey S Revenko, Lyndsey L Hanson, et al.
Bioorganic & Medicinal Chemistry Letters|June 26, 2012
Discovery of novel benzylidene-1,3-thiazolidine-2,4-diones as potent and selective inhibitors of the PIM-1, PIM-2, and PIM-3 protein kinasesLes A Dakin, Michael H Block, Huawei Chen, et al.
ACS Medicinal Chemistry Letters|June 6, 2014
Discovery of Disubstituted Imidazo[4,5-b]pyridines and Purines as Potent TrkA InhibitorsTao Wang, Michelle L Lamb, Michael H Block, et al.
Bioorganic & Medicinal Chemistry Letters|March 22, 2018
Discovery of 2,6-disubstituted pyrazine derivatives as inhibitors of CK2 and PIM kinasesLakshmaiah Gingipalli, Michael H Block, Larry Bao, et al.
Bioorganic & Medicinal Chemistry Letters|December 23, 2008
Identification of amidoheteroaryls as potent inhibitors of mutant (V600E) B-Raf kinase with in vivo activityPaul D Lyne, Brian Aquila, Donald J Cook, et al.
ACS Medicinal Chemistry Letters|June 6, 2014
Potent and Selective Inhibitors of CK2 Kinase Identified through Structure-Guided HybridizationJames E Dowling, Claudio Chuaqui, Timothy W Pontz, et al.
Pageof 5

Showing results (31-40 of 45) with videos related to

Sort By:
Pageof 5
Plos One|July 24, 2018
BRD4 amplification facilitates an oncogenic gene expression program in high-grade serous ovarian cancer and confers sensitivity to BET inhibitorsGarrett W Rhyasen, Yi Yao, Jingwen Zhang, et al.
Journal of Medicinal Chemistry|January 5, 2018
Adventures in Scaffold Morphing: Discovery of Fused Ring Heterocyclic Checkpoint Kinase 1 (CHK1) InhibitorsBin Yang, Melissa M Vasbinder, Alexander W Hird, et al.
Bioorganic & Medicinal Chemistry Letters|September 1, 2016
Modulating the strength of hydrogen bond acceptors to achieve low Caco2 efflux for oral bioavailability of PARP inhibitors blocking centrosome clusteringChungang Gu, Michelle L Lamb, Jeffrey W Johannes, et al.
ACS Medicinal Chemistry Letters|June 6, 2014
Structure and Property Based Design of Pyrazolo[1,5-a]pyrimidine Inhibitors of CK2 Kinase with Activity in VivoJames E Dowling, Marat Alimzhanov, Larry Bao, et al.
Science Translational Medicine|June 16, 2017
Targeting KRAS-dependent tumors with AZD4785, a high-affinity therapeutic antisense oligonucleotide inhibitor of KRASSarah J Ross, Alexey S Revenko, Lyndsey L Hanson, et al.
Bioorganic & Medicinal Chemistry Letters|June 26, 2012
Discovery of novel benzylidene-1,3-thiazolidine-2,4-diones as potent and selective inhibitors of the PIM-1, PIM-2, and PIM-3 protein kinasesLes A Dakin, Michael H Block, Huawei Chen, et al.
ACS Medicinal Chemistry Letters|June 6, 2014
Discovery of Disubstituted Imidazo[4,5-b]pyridines and Purines as Potent TrkA InhibitorsTao Wang, Michelle L Lamb, Michael H Block, et al.
Bioorganic & Medicinal Chemistry Letters|March 22, 2018
Discovery of 2,6-disubstituted pyrazine derivatives as inhibitors of CK2 and PIM kinasesLakshmaiah Gingipalli, Michael H Block, Larry Bao, et al.
Bioorganic & Medicinal Chemistry Letters|December 23, 2008
Identification of amidoheteroaryls as potent inhibitors of mutant (V600E) B-Raf kinase with in vivo activityPaul D Lyne, Brian Aquila, Donald J Cook, et al.
ACS Medicinal Chemistry Letters|June 6, 2014
Potent and Selective Inhibitors of CK2 Kinase Identified through Structure-Guided HybridizationJames E Dowling, Claudio Chuaqui, Timothy W Pontz, et al.
Pageof 5